Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients

We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P= 7.38 × 10−4). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P= 2.47 × 10−5). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

Download Full-text

Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1

Digestive Diseases ◽

10.1159/000439075 ◽

2015 ◽

Vol 33 (6) ◽

pp. 708-714 ◽

Cited By ~ 1

Author(s):

Naoshi Nishida ◽

Mina Iwanishi ◽

Tomohiro Minami ◽

Hirokazu Chishina ◽

Tadaaki Arizumi ◽

...

Keyword(s):

Hepatitis C ◽

Triple Therapy ◽

Virological Response ◽

Rapid Decline ◽

Hcv Rna ◽

Rapid Virological Response ◽

Virus Genotype ◽

Early Viral Response ◽

Triple Regimen ◽

Detectable Serum

Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naïve cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral load during treatment. Methods: Forty-six CHC patients with HCV genotype 1b were treated with PEG-IFN/RBV/SMV triple therapy: 20 were naïve cases, 12 were relapsers and 14 were non-responders to prior PEG-IFN/RBV therapy. We evaluated rapid virological response (RVR), complete early virological response (EVR), viral clearance at the end of the treatment (EOT) and at 12 weeks after the EOT (SVR12). In addition, we quantified the serum HCV-RNA on the 1st day and the 7th day after initiating treatment. Results: Multivariate analysis revealed that response to prior treatment was identified as an independent factor for achieving SVR12 after triple therapy (p = 0.0005). The achievement of serum HCV-RNA <2 log10 IU/ml on day 7, RVR, EVR and EOT were associated with SVR12 (p = 0.0050, p = 0.0002, p = 0.0009 and p = 0.0002, respectively). Conclusions: Rapid decline of HCV is a predictive factor for the achievement of SVR12, even in antiviral triple therapy with PEG-IFN/RBV/SMV. An extended treatment period should be applied for patients who show detectable serum HCV-RNA at week 4.

Download Full-text

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College ◽

10.37723/jumdc.v11i1.397 ◽

2020 ◽

Vol 11 (1) ◽

pp. 9-14

Author(s):

Muhammad Sarfraz ◽

Arshad Rabbani ◽

Muhammad Shahzad Manzoor ◽

Benish Adil

Keyword(s):

Treatment Response ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Rna ◽

Rapid Virological Response ◽

Genotype 3 ◽

Hcv Genotype ◽

End Of Treatment ◽

Treatment Naïve ◽

Hcv Genotype 3

BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological response (SVR 12). METHODOLOGY: This was a descriptive case study conducted in Liver OPD of Benazir Bhutto Hospital during 01 November 2018 to 30 April 2019 , in which 100 patients of HCV were enrolled, all of them had HCV genotype 3 infection. Every patient was treated with combination of Velpatasvir/Sofosbuvir 100mg/400 mg Once Daily as part of treatment regimen of HCV infection for 12 weeks. Pre-treatment HCV RNA QUANTITATIVE PCR was done, which was repeated on 4, 12 weeks of treatment and then 12 weeks post treatment. RESULTS: Among 100 patients, 51 (51%) were male and 49 (49%) were females. Mean age of patients was 43.2 ± 10.4 years (mean ± SD). Mean BMI of enrolled patients was 21.34 ± 2.40 kg/m2. 33% patients were cirrhotic while 67% were non cirrhotic. 53% patients were treatment experienced while 47% were treatment naïve. Rapid Virological Response (RVR) was achieved in 92%, End of treatment response (ETR) was achieved in 96%, while Sustained Virological response (SVR12) was achieved in 99% patients. The results were stratiﬁed according to age, gender and BMI. There was no eﬀect of these parameters on the ﬁnal results. CONCLUSION: Virological response (RVR, ETR, SVR12) of Velpatsvir /Sofosbuvir and Ribavirin is encouraging.

Download Full-text

Efficacy of Sofosbuvir, Daclatasvir and Ribavirin combination therapy in treatment naive hepatitis C patients at tertiary care hospital of South Punjab

10.1101/2021.11.23.21266653 ◽

2021 ◽

Author(s):

Qasim Umar ◽

Muhammad Asif Gul ◽

Farooq Mohyud Din Chaudhary ◽

Shehryar Kanju ◽

Rizwan Hameed ◽

...

Keyword(s):

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

Tertiary Care ◽

Decompensated Cirrhosis ◽

Hcv Rna ◽

Care Hospital ◽

Compensated Cirrhosis ◽

The World ◽

Treatment Naïve

Introduction: Hepatitis C has gradually become endemic in Pakistan, with infectivity rates one of the highest in the world. The emergence of direct acting antivirals (DAAs) has become a ray of sunshine in eradicating this menace from this region. The combination of sofosbuvir, daclatasvir and ribavirin (SOF/DACLA/RIBA) has had phenomenal success all over the world in eradicating this virus. Our study aims to see the effectiveness of this regime in this part of the world. Methods: After approval from the institutional review board (IRB), retrospective analysis of data of treatment naive patients who have been treated with the above mentioned regimen was collected to assess the efficacy by calculating the sustained virological response (SVR) at 12 weeks after completion of therapy. Results: Data of 300 patients (172 females, 128 males) was collected. Mean age was 39.66 years. Majority (almost 90%) of patients were from District Multan Age range was from 18 years to 60 years. Eighty-three percent of the patients were non-cirrhotics, 15.7% had compensated cirrhosis, while only 1 % had decompensated cirrhosis. Out of the 300 patients, 291 patients had undetectable HCV RNA on polymerase chain reaction (PCR) at 12 weeks after completion of treatment, achieving SVR rates of 97%. There was no significant association of SVR rates with gender and age of patients. Conclusion: The combination of SOF/DACA/RIBA is highly efficacious for treatment of hepatitis C patients. Key Words: sofosbuvir, daclatasvir, efficacy, sustained virological response, hepatitis C

Download Full-text

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

10.36106/5009819 ◽

2021 ◽

pp. 27-30

Author(s):

Manisha Thakur ◽

Anurag Chauhan ◽

Prashant Jambunathan ◽

Shikha Awasthi ◽

Thilagavathi K ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Sustained Viral Response ◽

Hcv Rna ◽

Hepatitis C Infection ◽

Genotype 3 ◽

Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

Download Full-text

509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study

Journal of Hepatology ◽

10.1016/s0168-8278(04)90509-0 ◽

2004 ◽

Vol 40 ◽

pp. 150 ◽

Cited By ~ 6

Author(s):

J.M. Sanchez-Tapias ◽

M. Diago ◽

P. Escartin ◽

J. Enriquez ◽

R. Moreno ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Prolonged Treatment ◽

Hcv Rna ◽

Treatment Naïve ◽

Peginterferon Alfa

Download Full-text

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients

BioMed Research International ◽

10.1155/2013/580796 ◽

2013 ◽

Vol 2013 ◽

pp. 1-6 ◽

Cited By ~ 3

Author(s):

Alessio Aghemo ◽

Elisabetta Degasperi ◽

Maria Grazia Rumi ◽

Enrico Galmozzi ◽

Luca Valenti ◽

...

Keyword(s):

Treatment Outcome ◽

Treatment Failure ◽

Virological Response ◽

Hcv Rna ◽

Rapid Virological Response ◽

Virus Genotype ◽

Viral Kinetics ◽

Treatment Naïve ◽

Baseline Predictor ◽

The Impact

Background. The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. The impact of baseline predictors of treatment outcome and their interplay with viral kinetics in HCV-1 CC patients has not been fully evaluated.Aim. To identify baseline and on-therapy predictors of treatment failure in HCV-1 IL28B CC patients.Methods. Treatment-naïve HCV-1 patients, compliant to PegIFN and Rbv who did not discontinue treatment for nonvirological reasons, were analyzed.Results. 109 HCV-1 IL28B CC were studied. Sixty were males, 39 with BMI >25, 69 with >600,000 IU/mL HCV RNA, 15 with HCV1a, and 30 with cirrhosis. Overall, 75 (69%) achieved an SVR; cirrhosis was the only baseline predictor of treatment failure (OR: 2.58, 95% CI: 1.07–6.21) as SVR rates were 53% in cirrhotics versus 75% in noncirrhotics (P=0.03). HCV RNA undetectability (<50 IU/mL) at week 4 (RVR) was achieved by 58 patients (53%). The SVR rates were independent of RVR in noncirrhotics, 76% (34/45) RVR (+) and 74% (25/34) RVR (−) (P=0.9). In cirrhotic patients, SVR rates were significantly higher in RVR (+) compared to RVR (−) (10/13 (77%) versus 6/17 (35%)P=0.03).Conclusions. In HCV-1 IL28B CC patients, cirrhosis is the only clinical baseline predictor of PegIFN and Rbv treatment failure. However, in IL28B CC cirrhotics, the achievement of RVR identifies those patients who still have high rates of SVR to Peg-IFN/Rbv therapy.

Download Full-text

Impact of IL28B-genotype on virological response in treatment-naive Austrian patients with chronic hepatitis C

Zeitschrift für Gastroenterologie ◽

10.1055/s-0030-1254636 ◽

2010 ◽

Vol 48 (05) ◽

Author(s):

A Staettermayer ◽

K Rutter ◽

S Beinhardt ◽

TM Scherzer ◽

K Zinober ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virological Response ◽

Il28b Genotype ◽

Treatment Naïve

Download Full-text

Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530320666200917113650 ◽

2020 ◽

Vol 20 ◽

Author(s):

Rehab Badawi ◽

Shaimaa Soliman ◽

Lobna Aboali ◽

Mahmoud Elkadeem ◽

Asem Elfert ◽

...

Keyword(s):

Liver Cirrhosis ◽

Chronic Hepatitis ◽

Platelet Count ◽

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Rna ◽

End Of Treatment ◽

Pugh Class ◽

Direct Acting

Background & Aims: This study aimed to assess the changes in platelet counts of patients with liver cirrhosis due to chronic HCV, who achieved sustained virological response (SVR) after taking direct acting antivirals (DAAs) in a large cohort study in Egypt. Methods: This multicenter observational retrospective study was carried out on 2500 chronic hepatitis C virus (HCV) infected patients who achieved (SVR) after treatment with direct acting antiviral drugs (DAA). HCV infection was confirmed by positive PCR for HCV RNA infection. SVR was defined as a negative PCR test for HCV-RNA 12 weeks after completion of DAA therapy. Platelets count was measured before therapy, during therapy, at the end of treatment, and 12 weeks after the end of the treatment. Results: There were 2186 patients enrolled in the study; 1866 (85.4%) were treatment naïve. There were 1006 (46%) males and 1180 (54%) females. Mean age was 50.82± 11.66 years, 2142 (98 %.0) patients achieved SVR, 2118 (96.9%) patients had Child -Pugh class A cirrhosis, and 68 (3.1%) had Child -Pugh class B liver cirrhosis. A significant increase of the platelets count was detected at the end of treatment in comparison to the pretreatment levels (P<0.001), and after achieving SVR (P <0.001) when compared to the pretreatment values. Conclusion: Improvement of platelets count occurs after HCV therapy with DAAS in patients with liver cirrhosis. These results suggested that HCV eradication may have a role in improvement of platelet count.

Download Full-text